Centessa Pharmaceuticals (CNTA) to Release Earnings on Thursday

Centessa Pharmaceuticals (NASDAQ:CNTA) will likely be releasing its earnings data before the market opens on Thursday, March 27th. Analysts expect Centessa Pharmaceuticals to post earnings of ($0.45) per share for the quarter.

Centessa Pharmaceuticals Price Performance

CNTA stock opened at $16.77 on Thursday. The company has a current ratio of 21.52, a quick ratio of 21.52 and a debt-to-equity ratio of 0.15. Centessa Pharmaceuticals has a one year low of $7.75 and a one year high of $19.09. The firm has a market capitalization of $2.21 billion, a PE ratio of -10.96 and a beta of 1.54. The firm has a 50-day moving average of $16.46 and a two-hundred day moving average of $16.36.

Insider Activity

In related news, General Counsel Iqbal J. Hussain sold 6,000 shares of the stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $15.29, for a total value of $91,740.00. Following the transaction, the general counsel now owns 118,265 shares in the company, valued at approximately $1,808,271.85. This represents a 4.83 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Saurabh Saha sold 55,000 shares of the stock in a transaction that occurred on Friday, December 20th. The stock was sold at an average price of $17.44, for a total value of $959,200.00. Following the completion of the transaction, the chief executive officer now owns 520,661 shares in the company, valued at $9,080,327.84. This represents a 9.55 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 260,168 shares of company stock worth $4,357,818 in the last 90 days. Company insiders own 11.59% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have commented on CNTA. TD Cowen began coverage on shares of Centessa Pharmaceuticals in a research note on Tuesday, January 7th. They set a “buy” rating for the company. Guggenheim reaffirmed a “buy” rating on shares of Centessa Pharmaceuticals in a research note on Monday, February 10th. Finally, Morgan Stanley reiterated an “overweight” rating and issued a $27.00 target price on shares of Centessa Pharmaceuticals in a report on Friday, March 7th. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $26.00.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.